| Title |
Investigation of Influencing Factors on Higher Placebo Response in East Asian Versus Western Clinical Trials for Partial Epilepsy: A Meta-Analysis
|
|---|---|
| Published in |
Clinical Drug Investigation, March 2013
|
| DOI | 10.1007/s40261-013-0077-x |
| Pubmed ID | |
| Authors |
Yosuke Tachibana, Mamoru Narukawa |
| Abstract |
Placebo response in clinical trials for anti-epileptic drugs (AEDs) has been examined and a recent meta-analysis revealed that East Asian trials showed unexpectedly higher placebo response. As multi-national trials have become common, it is important to understand placebo response in different settings, including regions/countries for future clinical trials. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 2 | 10% |
| United Kingdom | 1 | 5% |
| Unknown | 18 | 86% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 29% |
| Student > Ph. D. Student | 4 | 19% |
| Student > Bachelor | 3 | 14% |
| Librarian | 1 | 5% |
| Unspecified | 1 | 5% |
| Other | 3 | 14% |
| Unknown | 3 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 33% |
| Agricultural and Biological Sciences | 3 | 14% |
| Psychology | 3 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 10% |
| Economics, Econometrics and Finance | 1 | 5% |
| Other | 2 | 10% |
| Unknown | 3 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 May 2017.
All research outputs
#15,279,577
of 22,721,584 outputs
Outputs from Clinical Drug Investigation
#699
of 959 outputs
Outputs of similar age
#123,887
of 197,783 outputs
Outputs of similar age from Clinical Drug Investigation
#6
of 10 outputs
Altmetric has tracked 22,721,584 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 959 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,783 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.